RE: Response from Brooke17 Jan 2023 18:23
""clinical development path for SNG001 in patients hospitalised due to a severe viral lung infection including SARS-CoV-2, influenza, RSV, adenovirus, parainfluenza and rhinoviruses""
That seems quite a narrowing of patients being targeted for a trial and quite a narrowing of product sales if the trial was successful. So it doesn't seem to me that the billions of pounds of sales being discussed a year or so ago are now possible. Niche product with low sales - but only if a trial gets off the ground....